Cough Drops Market Report: Size, Share and Outlook by 2031

The cough drops market is projected to grow significantly, reaching an estimated US$ 3,600.88 million by 2031, up from US$ 2,231.58 million in 2023. This growth represents a compound annual growth rate (CAGR) of 6.2% from 2023 to 2031. Several key factors are propelling this market expansion, including the increasing prevalence of respiratory diseases that lead to sore throats and a growing trend towards self-medication. Additionally, the rising emphasis on natural ingredients and eco-friendly packaging is expected to further enhance market growth during the forecast period. However, challenges such as the inability of cough drops to provide long-term relief and the availability of alternative treatments may hinder market progress.

Common viral infections, including colds and influenza, are frequent culprits behind sore throats. A sore throat can also be a symptom of strep throat, allergies, or other upper respiratory conditions. The World Health Organization reports that around 1 billion cases of seasonal influenza occur globally each year, with 3-5 million cases classified as severe. Symptoms typically manifest 1-4 days post-infection and can last for about a week. The widespread nature of the common cold, flu, and seasonal allergies significantly drives the demand for cough relief products, as individuals seek quick alleviation from symptoms such as coughing and throat irritation.

Moreover, deteriorating air quality, exacerbated by rapid urbanization, poses a serious health concern worldwide, leading to an increase in respiratory illnesses. Airborne pollutants can aggravate conditions like asthma and bronchitis, resulting in more frequent coughing episodes. Consequently, there is a growing consumer demand for cough drops to alleviate these symptoms. The elderly population is particularly susceptible to respiratory issues due to weakened immune systems and pre-existing health conditions. The global demographic is aging at an unprecedented rate; according to WHO data from October 2022, it is projected that by 2030, 1 in 6 people worldwide will be aged 60 or older. The number of individuals in this age group is expected to rise from 1 billion in 2020 to 1.4 billion by 2030, and further to 2.1 billion by 2050. Additionally, the population aged 80 and above is anticipated to triple from 2020 to 2050, reaching 426 million. As people age, they are more likely to suffer from chronic illnesses that necessitate symptom management, including the use of cough drops for relief from coughs associated with infections or chronic conditions. An article in the Annals of Research Hospitals from 2018 highlights that the increasing prevalence of chronic lung diseases and iatrogenic immunosuppression is contributing to a rise in respiratory infections among the aging population. By 2050, it is estimated that 2 billion people will be over 65 years old, with over 1 billion individuals suffering from preventable chronic lung diseases.

In light of the growing incidence of respiratory disorders, cough drop manufacturers are innovating their product offerings and pursuing development strategies such as collaborations and partnerships to expand their market presence. For example, in June 2024, Vicks India, a subsidiary of Procter & Gamble, introduced the Vicks Double Power Cough Drops, a significant enhancement of their traditional triangular cough drops. These new drops were developed based on consumer feedback, addressing the demand for a larger size that effectively alleviates symptoms of throat irritation and cough. Thus, the increasing prevalence of respiratory diseases leading to sore throats is a key driver of growth in the cough drops market globally.

The comparative analysis of companies in the cough drops market categorizes it based on product offerings (including product satisfaction, features, and availability), recent market developments (such as mergers and acquisitions, new product launches, investments, collaborations, and expansions), and geographic presence. This analysis aids in informed decision-making and enhances understanding of the competitive landscape. The report delves into significant recent developments and innovations by leading vendors in the global cough drops market, including major players like Mondelez International Inc, The Procter & Gamble Co, GSK Plc, Cipla Ltd, Bliss GVS Pharma Ltd, Thornton & Ross, Reckitt Benckiser Group Plc, Sanofi SA, Gepach International, and Ricola.

The cough drops market is segmented by product type into gluten-free, sugar-free, and others. As of 2023, the sugar-free segment holds the largest market share. By application, the market is divided into adult and children segments, with adults representing the largest share in 2023. Distribution channels are categorized into offline and online, with offline sales dominating the market in 2023.

Companies in the cough drops market employ various organic and inorganic strategies to enhance their market presence. Organic strategies primarily involve product launches and approvals, while inorganic strategies include acquisitions, collaborations, and partnerships. These strategies enable market players to expand their operations and improve their geographic reach, contributing to overall market growth. Notable developments by key players in the cough drops market include:

• In September 2024, Cofsils, a brand under Cipla Health Ltd specializing in sore throat relief, launched a new flavor: Cofsils Mulethi. This lozenge features the soothing taste of Mulethi (Licorice) and provides rapid relief from sore throats. Cofsils Mulethi joins the existing flavor lineup, which includes Cofsils Fresh Mint, Cofsils Tulsi Pudina, and popular options like Cofsils Orange, Lemon Honey, and Ginger Lemon.